glp 1 2026 NEW FOR 2026: Medicare GLP-1 Bridge Program Access to eligible weight-loss medications for approximately $50/month* *Eligibility and physician approval required. Starting July 1, 2026, Medicare will launch a new temporary program called NEW FOR 2026: Medicare GLP-1

Compounded semaglutide may be prescribed by licensed healthcare providers and dispensed by state-licensed 503A compounding pharmacies when medically appropriate

Marketers in the health, wellness, and fitness spaces must pounce on the opportunity to frame their offerings as a better long-term bet than weight loss drugs.

The list of conditions for which GLP-1 drugs provides benefit independent of weight loss keeps growing

If a product has not been FDA-approved for a specific condition, it cannot be promoted as safe or effective for that condition

2023 brought with it many medical advances, including the "skinny shot" for weight loss, known in its various formulations as the brand names Ozempic, Wegovy, Mounjaro and others